SXTC Stock: China SXT Pharmaceuticals, Inc. Stock Price, Analysis & Insights
Get live sxtc stock price $1.34, comprehensive China SXT Pharmaceuticals, Inc. stock analysis, charts, news, and expert forecast. Real-time sxtc stock data and investment insights.
Loading chart...
Company Overview
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.
Company Information
- CEO
- Feng Zhou
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 75
Contact Information
- Website
- https://www.sxtchina.com
- Address
- 178 North Taidong Road
- Country
- CN
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 1.46)
Business Model & Strategy
China SXT Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Feng Zhou, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Drug Manufacturers - Specialty & Generic model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
China SXT Pharmaceuticals, Inc. competes in the Drug Manufacturers - Specialty & Generic within the broader Healthcare. With 155.5 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, China SXT Pharmaceuticals, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating China SXT Pharmaceuticals, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for China SXT Pharmaceuticals, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for China SXT Pharmaceuticals, Inc.
- ⚠Investors should consider how China SXT Pharmaceuticals, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
155.48M
P/E Ratio
-0.58
Beta
1.46
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 155.48M market capitalization
- Trading Volume: 174.39K shares traded today
- Price Range: 52-week range of $0.30 - $5.70
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for China SXT Pharmaceuticals, Inc.
China SXT Pharmaceuticals, Inc. (SXTC) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. With a current market capitalization of 155.48M, the company represents a significant player in its market. The stock is currently trading at $1.34 with a negativedaily change of 16.25%.
The company's 75 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.58, beta of 1.46, and 52-week price range from $0.30 to $5.70when evaluating investment opportunities.
Why Invest in China SXT Pharmaceuticals, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Feng Zhou
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.